Base de dados : MEDLINE
Pesquisa : E02.774 [Categoria DeCS]
Referências encontradas : 6782 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 679 ir para página                         

  1 / 6782 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390261
[Au] Autor:Rui W; Xiangyu D; Fang X; Long G; Yi Y; Wenjuan W; Tian H; Xiaoning Z; Yong Z; Jianfeng F; Hengjin L; Chengxin L
[Ad] Endereço:Department of Dermatology, Chinese PLA General Hospital, Medical College of Chinese PLA, Beijing, China.
[Ti] Título:Metabolic syndrome affects narrow-band UVB phototherapy response in patients with psoriasis.
[So] Source:Medicine (Baltimore);96(50):e8677, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Psoriasis is a chronic inflammatory skin disease. Metabolic syndrome (MS) is a combination of central obesity, dyslipidemia, glucose intolerance, and elevated blood pressure. Many epidemiological surveys have revealed the association of psoriasis with MS. Narrowband ultraviolet radiation b (NB-UVB) is an effective and widely used treatment for psoriasis. The purpose of this study was to investigate whether the presence of MS in patient with psoriasis affects NB-UVB treatment and whether this syndrome correlates with systemic inflammation.From June 2016 to December 2016, 243 adults with a diagnosis of psoriasis vulgaris eligible to treatment with NB-UVB were admitted to the phototherapy unit of Dermatology department, Chinese PLA General Hospital. Fifty-five included patients were grouped based on the presence of MS. They accepted the treatment of NB-UVB and the following data were collected: serum levels of IL-17 (interleukin), TNF-α (tumor necrosis factor) and IL-6, Psoriasis Area and Severity Index (PASI) scores before and after 10 sections of NB-UVB treatment.Significant PASI improvement was observed in psoriatic patients without MS after 10 sections of phototherapy, while patients with MS showed a less improvement (P < .001). There was statistically significant difference in percentage of patients achieving 50% reduction in PASI scores between the 2 groups (P < .05). Multivariate logistic regression analysis showed MS was an independent factor that affecting the treatment of NB-UVB (P < .05). Psoriatic patients with MS showed a much less reduction of IL-17 and IL-6 before and after 10 sections of NB-UVB treatment respectively than patients without MS (P < .05).Psoriatic patients with MS have poorer improvement in comparison those without MS using NB-UVB treatment. MS was an independent factor that affecting the treatment of NB-UVB. In addition, psoriatic patients with MS showed a much less reduction of systemic biomarkers (interleukin-IL-17, TNF-α, IL-6) than patients without MS. Namely, they may need a longer course of treatment to achieve improved skin lesions.
[Mh] Termos MeSH primário: Síndrome Metabólica/complicações
Fototerapia
Psoríase/terapia
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Feminino
Seres Humanos
Interleucina-17/sangue
Interleucina-6/sangue
Masculino
Psoríase/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Biomarkers); 0 (Interleukin-17); 0 (Interleukin-6)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008677


  2 / 6782 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29177301
[Au] Autor:Sun W; Zeng X; Wu S
[Ad] Endereço:Max Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany. wusi@mpip-mainz.mpg.de.
[Ti] Título:Photoresponsive ruthenium-containing polymers: potential polymeric metallodrugs for anticancer phototherapy.
[So] Source:Dalton Trans;47(2):283-286, 2018 Jan 02.
[Is] ISSN:1477-9234
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This Frontier presents the recent development of photoresponsive Ru-containing polymers for cancer treatment. These novel Ru-containing polymers are prepared by introducing photoresponsive Ru complexes into polymers. Based on their chemical structures in aqueous solutions, these polymers can self-assemble into different nanostructures. The self-assembled nanostructures can circulate in the blood stream, accumulate at tumor tissue, and can be taken up by tumor cells. Red light, which can penetrate into tissue deeply, can induce the photodissociation of these polymers and sensitize singlet oxygen ( O ) generation. Both dissociated Ru complexes and generated O can inhibit the growth of tumor cells. Photoresponsive Ru-containing polymers provide a new platform for combined photodynamic therapy and photoactivated chemotherapy. The design strategies, self-assembly, photoresponsiveness, and anticancer effects of these polymers are introduced. Some remaining challenges for Ru-containing polymers for phototherapy are discussed.
[Mh] Termos MeSH primário: Neoplasias/terapia
Compostos Organometálicos/química
Compostos Organometálicos/farmacologia
Fármacos Fotossensibilizantes/química
Fármacos Fotossensibilizantes/farmacologia
Fototerapia/métodos
Rutênio/química
[Mh] Termos MeSH secundário: Compostos Organometálicos/uso terapêutico
Fármacos Fotossensibilizantes/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Organometallic Compounds); 0 (Photosensitizing Agents); 7UI0TKC3U5 (Ruthenium)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1039/c7dt03390g


  3 / 6782 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452928
[Au] Autor:Vats M; Mishra SK; Baghini MS; Chauhan DS; Srivastava R; De A
[Ad] Endereço:Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai 410210, India. muktivatsiitb@gmail.com.
[Ti] Título:Near Infrared Fluorescence Imaging in Nano-Therapeutics and Photo-Thermal Evaluation.
[So] Source:Int J Mol Sci;18(5), 2017 Apr 28.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The unresolved and paramount challenge in bio-imaging and targeted therapy is to clearly define and demarcate the physical margins of tumor tissue. The ability to outline the healthy vital tissues to be carefully navigated with transection while an intraoperative surgery procedure is performed sets up a necessary and under-researched goal. To achieve the aforementioned objectives, there is a need to optimize design considerations in order to not only obtain an effective imaging agent but to also achieve attributes like favorable water solubility, biocompatibility, high molecular brightness, and a tissue specific targeting approach. The emergence of near infra-red fluorescence (NIRF) light for tissue scale imaging owes to the provision of highly specific images of the target organ. The special characteristics of near infra-red window such as minimal auto-fluorescence, low light scattering, and absorption of biomolecules in tissue converge to form an attractive modality for cancer imaging. Imparting molecular fluorescence as an exogenous contrast agent is the most beneficial attribute of NIRF light as a clinical imaging technology. Additionally, many such agents also display therapeutic potentials as photo-thermal agents, thus meeting the dual purpose of imaging and therapy. Here, we primarily discuss molecular imaging and therapeutic potentials of two such classes of materials, i.e., inorganic NIR dyes and metallic gold nanoparticle based materials.
[Mh] Termos MeSH primário: Nanoestruturas/química
Neoplasias/diagnóstico por imagem
Espectroscopia de Luz Próxima ao Infravermelho
[Mh] Termos MeSH secundário: Portadores de Fármacos/química
Corantes Fluorescentes/química
Corantes Fluorescentes/uso terapêutico
Seres Humanos
Nanopartículas Metálicas/química
Nanopartículas Metálicas/uso terapêutico
Nanoestruturas/uso terapêutico
Neoplasias/tratamento farmacológico
Fotoquimioterapia
Fototerapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Drug Carriers); 0 (Fluorescent Dyes)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180122
[Lr] Data última revisão:
180122
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  4 / 6782 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29283336
[Au] Autor:Christie C; Madsen SJ; Peng Q; Hirschberg H
[Ad] Endereço:Beckman Laser Institute, University of California, Irvine, 1002 Health Sciences Rd. E, Irvine, CA 92612.
[Ti] Título:Photothermal Therapy Employing Gold Nanoparticle- Loaded Macrophages as Delivery Vehicles: Comparing the Efficiency of Nanoshells Versus Nanorods.
[So] Source:J Environ Pathol Toxicol Oncol;36(3):229-235, 2017.
[Is] ISSN:2162-6537
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Macrophages (Ma) loaded with gold based nanoparticles, which convert near infrared light to heat, have been studied as targeted transport vectors for photothermal therapy (PTT) of tumors. The purpose of the experiments reported here was to compare the efficacy of gold-silica nanoshells (AuNS) and gold nanorods (AuNR) in macrophage mediated PTT. PTT efficacy was evaluated in hybrid glioma spheroids consisting of human glioma cells and either AuNS or AuNR loaded Ma, designated MaNS and MaNR respectivly. Spheroids were irradiated for 10 min. with light from an 810 nm diode laser at irradiances ranging from 0 to 28 W/cm2. PTT efficacy was determined from spheroid growth over a 14-day period. The uptake by Ma of pegylated AuNR (3.9 ± 0.9 %) was twice that of pegylated AuNS, (7.9 ± 0.7 %). Hybrid spheroids consisting of a 5:1 ratio of glioma cells to loaded Ma exhibited significant growth inhibition with MaNS when subjected to irradiances of 7 W/cm2 or greater. In contrast, no significant growth inhibition was observed for the MaNR hybrid spheroids at this 5:1 ratio, even at the highest irradiance investigated (28 W/cm2). Although AuNR were taken up by Ma in larger numbers then AuNS, MaNS were shown to have greater PTT efficacy compared to MaNR for equivalent numbers of loaded Ma.
[Mh] Termos MeSH primário: Neoplasias Encefálicas/terapia
Glioma/terapia
Ouro/administração & dosagem
Hipertermia Induzida/métodos
Macrófagos
Nanopartículas Metálicas/administração & dosagem
Nanoconchas/administração & dosagem
Nanotubos
Fototerapia/métodos
[Mh] Termos MeSH secundário: Animais
Linhagem Celular
Linhagem Celular Tumoral
Seres Humanos
Camundongos
Veículos Farmacêuticos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pharmaceutical Vehicles); 7440-57-5 (Gold)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171229
[St] Status:MEDLINE
[do] DOI:10.1615/JEnvironPatholToxicolOncol.2017021545


  5 / 6782 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29091565
[Au] Autor:van Zuuren EJ
[Ad] Endereço:From the Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
[Ti] Título:Rosacea.
[So] Source:N Engl J Med;377(18):1754-1764, 2017 Nov 02.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Rosácea/terapia
[Mh] Termos MeSH secundário: Administração Tópica
Adulto
Antibacterianos/uso terapêutico
Anti-Hipertensivos/uso terapêutico
Fármacos Dermatológicos/uso terapêutico
Feminino
Seres Humanos
Masculino
Fenótipo
Fototerapia
Guias de Prática Clínica como Assunto
Rinofima
Rosácea/classificação
Rosácea/tratamento farmacológico
Protetores Solares/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Antihypertensive Agents); 0 (Dermatologic Agents); 0 (Sunscreening Agents)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171102
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMcp1506630


  6 / 6782 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29049716
[Au] Autor:Caballero S; Kent DL; Sengupta N; Li Calzi S; Shaw L; Beli E; Moldovan L; Dominguez JM; Moorthy RS; Grant MB
[Ad] Endereço:Pharmacology and Therapeutics, University of Florida, Gainesville, Florida, United States.
[Ti] Título:Bone Marrow-Derived Cell Recruitment to the Neurosensory Retina and Retinal Pigment Epithelial Cell Layer Following Subthreshold Retinal Phototherapy.
[So] Source:Invest Ophthalmol Vis Sci;58(12):5164-5176, 2017 Oct 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: We investigated whether subthreshold retinal phototherapy (SRPT) was associated with recruitment of bone marrow (BM)-derived cells to the neurosensory retina (NSR) and RPE layer. Methods: GFP chimeric mice and wild-type (WT) mice were subjected to SRPT using a slit-lamp infrared laser. Duty cycles of 5%, 10%, 15%, and 20% (0.1 seconds, 250 mW, spot size 50 µm) with 30 applications were placed 50 to 100 µm from the optic disc. In adoptive transfer studies, GFP+ cells were given intravenously immediately after WT mice received SRPT. Immunohistochemistry was done for ionized calcium-binding adapter molecule-1 (IBA-1+), CD45, Griffonia simplicifolia lectin isolectin B4, GFP or cytokeratin). Expression of Ccl2, Il1b, Il6, Hspa1a, Hsp90aa1, Cryab, Hif1a, Cxcl12, and Cxcr4 mRNA and flow cytometry of the NSR and RPE-choroid were performed. Results: Within 12 to 24 hours of SRPT, monocytes were detected in the NSR and RPE-choroid. Detection of reparative progenitors in the RPE occurred at 2 weeks using flow cytometry. Recruitment of GFP+ cells to the RPE layer occurred in a duty cycle-dependent manner in chimeric mice and in mice undergoing adoptive transfer. Hspa1a, Hsp90aa1, and Cryab mRNAs increased in the NSR at 2 hours post laser; Hif1a, Cxcl12, Hspa1a increased at 4 hours in the RPE-choroid; and Ccl2, Il1b, Ifng, and Il6 increased at 12 to 24 hours in the RPE-choroid. Conclusions: SRPT induces monocyte recruitment to the RPE followed by hematopoietic progenitor cell homing at 2 weeks. Recruitment occurs in a duty cycle-dependent manner and potentially could contribute to the therapeutic efficacy of SRPT.
[Mh] Termos MeSH primário: Células da Medula Óssea/fisiologia
Movimento Celular/fisiologia
Fototerapia
Retina/citologia
Epitélio Pigmentado da Retina/citologia
[Mh] Termos MeSH secundário: Transferência Adotiva
Animais
Biomarcadores/metabolismo
Células Cultivadas
Quimiocina CXCL12/metabolismo
Corioide/citologia
Corioide/metabolismo
Feminino
Citometria de Fluxo
Proteínas de Fluorescência Verde/metabolismo
Proteínas de Choque Térmico/metabolismo
Transplante de Células-Tronco Hematopoéticas
Imuno-Histoquímica
Terapia a Laser
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Transgênicos
Monócitos/fisiologia
Receptores CXCR4/metabolismo
Retina/metabolismo
Retina/cirurgia
Epitélio Pigmentado da Retina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (CXCR4 protein, mouse); 0 (Chemokine CXCL12); 0 (Cxcl12 protein, mouse); 0 (Heat-Shock Proteins); 0 (Receptors, CXCR4); 147336-22-9 (Green Fluorescent Proteins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171020
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.16-20736


  7 / 6782 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29029903
[Au] Autor:Zhang M; Goyert G; Lim HW
[Ad] Endereço:Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.
[Ti] Título:Folate and phototherapy: What should we inform our patients?
[So] Source:J Am Acad Dermatol;77(5):958-964, 2017 Nov.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Ultraviolet (UV) degradation of folate has been studied in vitro and in vivo, but comprehensive reviews of the subject and recommendations for supplementing folate are lacking, especially for women of childbearing age, in whom decreases in folate predisposes newborns to neural tube defects. OBJECTIVE: We reviewed the effects of phototherapy on folate and provide a recommendation for women of childbearing age on phototherapy. METHODS: PubMed was searched for in vivo studies comparing folate levels before and after phototherapy. RESULTS: There is no evidence of decreased folate levels after UVA exposure. Decreased folate levels after sun exposure were limited to subjects taking folate supplements. Studies using narrowband UVB showed mixed results, potentially explained by dose-dependent degradation of folate; exposure >40 J/cm cumulatively and >2 J/cm per treatment were associated with 19%-27% decreases in serum folate levels, while lower doses did not affect folate levels. LIMITATIONS: Extensive variability in results from studies and lack of considering confounders. CONCLUSIONS: We recommend all women of childbearing age on phototherapy take 0.8 mg/day of folate supplements, as suggested by current guidelines for women of childbearing age, to reduce the risk of neural tube defects in unplanned pregnancy.
[Mh] Termos MeSH primário: Suplementos Nutricionais
Ácido Fólico/metabolismo
Ácido Fólico/efeitos da radiação
Terapia Ultravioleta/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Feminino
Ácido Fólico/sangue
Seres Humanos
Defeitos do Tubo Neural/prevenção & controle
Fototerapia/métodos
Gravidez
Resultado do Tratamento
Terapia Ultravioleta/métodos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
935E97BOY8 (Folic Acid)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171015
[St] Status:MEDLINE


  8 / 6782 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29019882
[Au] Autor:Hwang YF; Wu NY; Lee PY
[Ad] Endereço:aDepartment of Orthopedics bResearch Assistant Center, Show-Chwan Memorial Hospital, Changhua cInstitute of Biomedical Informatics, National Yang-Ming University, Taipei dDepartment of Biomedical Engineering, National Cheng Kung University, Tainan, Taiwan.
[Ti] Título:Koebner phenomenon induced by failed revisional orthopedic surgery but remitted with bone union: A case report.
[So] Source:Medicine (Baltimore);96(41):e8138, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Trauma or surgical incision might cause Koebner phenomenon (KP) in patients with cutaneous diseases, but seldom studies reported KP induced by repeated orthopedic surgery. PATIENT CONCERNS: The 22-year-old man did not have any prior histories of cutaneous diseases. Two months after the revision surgery for nonunion of the left femoral shaft fracture, KP was noted by psoriasis presented at the surgical scar, left thigh, scalp, and trunk. Phototherapy and topical treatments were prescribed but the effect was limited. DIAGNOSIS: KP induced by failed revisional orthopedic surgery. INTERVENTIONS: Because of implant failure, he underwent the second revision surgery, which was performed on the previous scar surrounded and covered by psoriatic plaques. OUTCOMES: After the second revision surgery successfully corrected the orthopedic problem, the psoriatic lesion remitted along with the bone union. LESSONS: In a patient having KP, to perform an operation on psoriatic lesion sites was safe and the surgical wound could heal well. The most important to treat KP induced by orthopedic surgery might be the underlying bone stability.
[Mh] Termos MeSH primário: Fármacos Dermatológicos/administração & dosagem
Fraturas do Fêmur/cirurgia
Fraturas Mal-Unidas/cirurgia
Procedimentos Ortopédicos
Fototerapia/métodos
Complicações Pós-Operatórias
Psoríase
Reoperação
[Mh] Termos MeSH secundário: Administração Tópica
Fraturas Mal-Unidas/diagnóstico
Fraturas Mal-Unidas/etiologia
Seres Humanos
Masculino
Procedimentos Ortopédicos/efeitos adversos
Procedimentos Ortopédicos/métodos
Complicações Pós-Operatórias/diagnóstico
Complicações Pós-Operatórias/etiologia
Complicações Pós-Operatórias/terapia
Psoríase/diagnóstico
Psoríase/etiologia
Psoríase/terapia
Reoperação/efeitos adversos
Reoperação/métodos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dermatologic Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171122
[Lr] Data última revisão:
171122
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171012
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008138


  9 / 6782 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28885372
[Au] Autor:Mateen FJ; Manalo NC; Grundy SJ; Houghton MA; Hotan GC; Erickson H; Videnovic A
[Ad] Endereço:aNeurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital bHarvard Medical School, Boston, MA cDepartment of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA.
[Ti] Título:Light therapy for multiple sclerosis-associated fatigue: Study protocol for a randomized controlled trial.
[So] Source:Medicine (Baltimore);96(36):e8037, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Fatigue is the most commonly reported symptom among multiple sclerosis (MS) patients, more than a quarter of whom consider fatigue to be their most disabling symptom. However, there are few effective treatment options for fatigue. We aim to investigate whether supplemental exposure to bright white light will reduce MS-associated fatigue. METHODS: Eligible participants will have clinically confirmed multiple sclerosis based on the revised McDonald criteria (2010) and a score ≥36 on the Fatigue Severity Scale (FSS). Participants will be randomized 1:1 to bright white light (10,000 lux; active condition) or dim red light (<300 lux; control condition) self-administered for 1 hour twice daily. The study will include a 2-week baseline period, a 4-week treatment period, and a 4-week washout period. Participants will record their sleep duration, exercise, caffeine, and medication intake daily. Participants will record their fatigue using the Visual Analogue Fatigue Scale (VAFS) 4 times every third day, providing snapshots of their fatigue level at different times of day. Participants will self-report their fatigue severity using FSS on 3 separate visits: at baseline (week 0), following completion of the treatment phase (week 6), and at study completion (week 10). The primary outcome will be the change in the average FSS score after light therapy. We will perform an intention-to-treat analysis, comparing the active and control groups to assess the postintervention difference in fatigue levels reported on FSS. Secondary outcome measures include change in global VAFS scores during the light therapy and self-reported quality of life in the Multiple Sclerosis Quality of Life-54. DISCUSSION: We present a study design and rationale for randomizing a nonpharmacological intervention for MS-associated fatigue, using bright light therapy. The study limitations relate to the logistical issues of a self-administered intervention requiring frequent participant self-report in a relapsing condition. Ultimately, light therapy for the treatment of MS-associated fatigue may provide a low-cost, noninvasive, self-administered treatment for one of the most prevalent and burdensome symptoms experienced by people with MS.
[Mh] Termos MeSH primário: Fadiga/complicações
Fadiga/terapia
Esclerose Múltipla/complicações
Esclerose Múltipla/terapia
Fototerapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Seres Humanos
Masculino
Meia-Idade
Esclerose Múltipla/psicologia
Seleção de Pacientes
Projetos de Pesquisa
Índice de Gravidade de Doença
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170909
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008037


  10 / 6782 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28837765
[Au] Autor:Panikkanvalappil SR; Hooshmand N; El-Sayed MA
[Ad] Endereço:Laser Dynamics Laboratory, School of Chemistry and Biochemistry, Georgia Institute of Technology , Atlanta, Georgia 30332, United States.
[Ti] Título:Intracellular Assembly of Nuclear-Targeted Gold Nanosphere Enables Selective Plasmonic Photothermal Therapy of Cancer by Shifting Their Absorption Wavelength toward Near-Infrared Region.
[So] Source:Bioconjug Chem;28(9):2452-2460, 2017 Sep 20.
[Is] ISSN:1520-4812
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Despite the important applications of near-infrared (NIR) absorbing nanomaterials in plasmonic photothermal therapy (PPT), their high yield synthesis and nonspecific heating during the active- and passive-targeted cancer therapeutic strategies remain challenging. In the present work, we systematically demonstrate that in situ aggregation of typical non-NIR absorbing plasmonic nanoparticles at the nuclear region of the cells could translate them into an effective NIR photoabsorber in plasmonic photothermal therapy of cancer due to a significant shift of the plasmonic absorption band to the NIR region. We evaluated the potential of nuclear-targeted AuNSs as photoabsorber at various stages of endocytosis by virtue of their inherent in situ assembling capabilities at the nuclear region of the cells, which has been considered as one of the most thermolabile structures within the cells, to selectively destruct cancer cells with minimal damage to healthy cells. Various plasmonic nanoparticles such as rods and cubes have been exploited to elucidate the role of plasmonic field coupling in assembled nanoparticles and their subsequent killing efficiency. The NIR absorbing capabilities of aggregated AuNSs have been further demonstrated both experimentally and theoretically using discrete dipolar approximation (DDA) techniques, which was in concordance with the observed results in plasmonic photothermal therapeutic studies. While the current work was able to demonstrate the utility of non-NIR absorbing plasmonic nanoparticles as a potential alternative for plasmonic photothermal therapy by inducing localized plasmonic heating at the nuclear region of the cells, these findings could potentially open up new possibilities in developing more efficient nanoparticles for efficient cancer treatment modalities.
[Mh] Termos MeSH primário: Núcleo Celular/patologia
Ouro/metabolismo
Hipertermia Induzida/métodos
Nanosferas/metabolismo
Neoplasias/terapia
Fototerapia/métodos
[Mh] Termos MeSH secundário: Linhagem Celular Tumoral
Núcleo Celular/metabolismo
Ouro/análise
Seres Humanos
Raios Infravermelhos
Nanosferas/análise
Nanosferas/ultraestrutura
Neoplasias/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
7440-57-5 (Gold)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171009
[Lr] Data última revisão:
171009
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.1021/acs.bioconjchem.7b00427



página 1 de 679 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde